Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Recursion Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Details : Under the licensing agreement, Recursion will be able to work on a new chemical compound for research and development purposes. This compound signifies a novel approach to treating fibrotic diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Recursion Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement